Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

NCT00057343 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Zevalin (ibritumomab tiuxetan)
DRUG: Rituxan (rituximab)

Sponsor

Biogen